<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892655</url>
  </required_header>
  <id_info>
    <org_study_id>LB1802</org_study_id>
    <nct_id>NCT03892655</nct_id>
  </id_info>
  <brief_title>Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer</brief_title>
  <acronym>LB1802</acronym>
  <official_title>A Multicenter, Prospective, Real World, National Study to Assess the Efficacy and Safety of Adjuvant Biosimilar Tratuzumab (Zedora) Treatment in Patients With Localized Her2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Libbs Farmacêutica LTDA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Libbs Farmacêutica LTDA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zedora registration was based on studies of women with metastatic breast cancer, but its
      approval includes adjuvant treatment. Thus, prospective data of drug use in localized disease
      are lacking, as well as are real-world safety and efficacy data, taking into consideration
      comorbidities and compliance difficulties.

      This will be an observational study of patients receiving adjuvant Zedora at several
      Brazilian institutions for the purpose of describing its efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational, multicenter, prospective, real-world study at Brazilian institutions.

      Adult patients with early HER2+ breast cancer receiving adjuvant biosimilar trastuzumab
      (Zedora) at the participating sites after the start of the study and meeting the eligibility
      criteria will be invited to participate. Demographics, comorbidities, disease history, extent
      of exposure to biosimilar trastuzumab (Zedora), adverse events and LVEF values will be
      collected.

      Data collection will be performed using a case report form (CRF) specifically designed for
      the study.

      Study Treatment:

      Biosimilar trastuzumab (Zedora) must be prescribed at the dosage described in the product
      label.

      Treatment duration will be 12 months for patients starting upfront with biosimilar
      trastuzumab (Zedora). Patients switching at any time to biosimilar trastuzumab (Zedora) after
      a period of adjuvant or neoadjuvant Herceptin® use will also be included in the overall
      analysis and subsequently assessed in a subgroup analysis.

      Sample Size:

      Number of patients = 170 Given the inexistence of a specific hypothesis to be tested, the
      statistical analysis will be basically descriptive.

      Sample size is based on the two-sided 95% confidence interval (95% CI) for the invasive
      disease relapse-free survival rate.

      The table below shows the 95% CIs for different rates in a sample of 170 patients, with an
      interval size ranging between 9% and 15%.

      Based on literature, a 3-year relapse-free survival between 88 and 96% is expected. According
      to the table above, a sample of 170 patients allows assessing this endpoint with +/- 6.0%
      accuracy.

      Study duration:

      The estimated time for patient enrollment in the study is one year and may be extended in
      case the sample size is not reached in this period. Biosimilar trastuzumab (Zedora) must be
      prescribed according to the product label and treatment duration will be up to one year. The
      patient will be maintained in the study for 5 years (from start of treatment), unless there
      is tumor recurrence (local or distant).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Efficacy endpoints: Invasive disease relapse-free survival rate</measure>
    <time_frame>18 months</time_frame>
    <description>Invasive disease relapse-free survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoints: Invasive disease relapse-free survival rate</measure>
    <time_frame>24 months</time_frame>
    <description>Invasive disease relapse-free survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoints: Invasive disease relapse-free survival rate</measure>
    <time_frame>30 months</time_frame>
    <description>Invasive disease relapse-free survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoints: Invasive disease relapse-free survival rate</measure>
    <time_frame>36 months</time_frame>
    <description>Invasive disease relapse-free survival rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoints: Invasive disease relapse-free survival after curative-intent surgery</measure>
    <time_frame>5 years</time_frame>
    <description>Invasive disease relapse-free survival after curative-intent surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoints: Overall survival after curative intent surgery</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival after curative intent surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints: Incidence of Related Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of Related Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints: Total cycles per patient</measure>
    <time_frame>5 years</time_frame>
    <description>Total cycles per patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoints: Incidence of dose interruption</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of dose interruption</description>
  </primary_outcome>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult female patients with diagnosis of early stage I to III HER2+ breast cancer confirmed
        by histopathology test, immunohistochemistry test and FISH, where required, according to
        local guidelines, and who have started biosimilar trastuzumab (Zedora) as neoadjuvant or
        adjuvant therapy according to the product label will be eligible for the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients aged 18 years and over

          -  diagnosis of early stage I to III breast cancer confirmed by histopathology test
             according to local guidelines.

          -  human epidermal growth factor receptor 2 (HER2)-positive tumor by immunohistochemistry
             or FISH (Fluorescence In Situ Hybridization), as per the 2018 ASCO assessment
             guideline [J Clin Oncol 36:2105, 2018].

          -  use of at least one dose of biosimilar trastuzumab (Zedora) as adjuvant therapy,
             regardless of previous neoadjuvant trastuzumab or Zedora use or the type of
             chemotherapy combined with the antibody.

          -  Signing of the informed consent form (ICF).

        Exclusion Criteria:

          -  use of biosimilar trastuzumab (Zedora) differently from the provisions in the label.

          -  patients enrolled in and followed up by Programa Vida Plena [Full Life Program].
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Augusto T Figueiredo, Analyst</last_name>
    <phone>55 11 2109 2500</phone>
    <phone_ext>1246</phone_ext>
    <email>augusto.figueiredo@libbs.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivienne C Castilho, Manager</last_name>
    <phone>55 11 2109 2500</phone>
    <phone_ext>1568</phone_ext>
    <email>vivienne.castilho@libbs.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>William Hiromi Fuzita</name>
      <address>
        <city>Manaus</city>
        <state>Amazonas</state>
        <zip>69057205</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia M Ono, DDS PhD</last_name>
      <email>isenp@isenp.org</email>
    </contact>
    <investigator>
      <last_name>William H Fuzita, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daniel Fontes Santos de Teive e Argolo</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41810570</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Argolo, Dr</last_name>
      <phone>55 71 2141-5941</phone>
      <email>'daniel.argolo@clion.com.br'</email>
    </contact>
    <contact_backup>
      <last_name>Aline Nascimento</last_name>
      <phone>55 71 2141-5941</phone>
      <email>pesquisa@clion.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Argolo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Márcia Cristina Colares Régis de Araújo</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60135285</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genilson Monteiro</last_name>
      <phone>85987858665</phone>
      <email>pesquisa@colv.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Genilson Monteiro</last_name>
      <phone>85998509342</phone>
      <email>pesquisa@colv.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Márcia Araújo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>João Paulo Vendas Villalba</name>
      <address>
        <city>Campo Grande</city>
        <state>MS</state>
        <zip>79002390</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>João P Villalba, Dr</last_name>
      <phone>55 67 41413499</phone>
      <email>joaopaulo@nio.med.br</email>
    </contact>
    <contact_backup>
      <last_name>Thais Lopes, MSc</last_name>
      <phone>55 67 41413499</phone>
      <email>thaislopes@nio.med.br</email>
    </contact_backup>
    <investigator>
      <last_name>João P Villalba, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sâmio Pimentel Ferreira</name>
      <address>
        <city>Belém</city>
        <state>Pará</state>
        <zip>66035265</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabia Assunção</last_name>
      <phone>91 3232 1009</phone>
      <email>fabiadearaujo@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Eliude Nascimento</last_name>
      <email>doutoraeli@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sâmio Pimentel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cláudio Rocha</name>
      <address>
        <city>Teresina</city>
        <state>Piaui</state>
        <zip>64049-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cláudio Rocha, Doctor</last_name>
      <phone>+55 86 3194-500</phone>
      <email>vencerpesquisaclinica@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fernanda Bitencourt</last_name>
      <phone>+55 86 3194-500</phone>
      <email>vencerpesquisaclinica@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cláudio Rocha, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Danielli de Almeida Matias</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <zip>59075740</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielli A Matias, Dr</last_name>
      <phone>55 84 4009 7401</phone>
      <email>dani25matias@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Danielli A Matias, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tomás Reinert</name>
      <address>
        <city>Caxias Do Sul</city>
        <state>Rio Grande Do Sul</state>
        <zip>95020450</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Binoto</last_name>
      <phone>55 54 984373022</phone>
      <email>monique.binotto@devita.com.br</email>
    </contact>
    <investigator>
      <last_name>Tomas Reinert, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Giuliano Santos Borges</name>
      <address>
        <city>Itajaí</city>
        <state>Santa Catarina</state>
        <zip>88301220</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliano S Borges, Dr</last_name>
      <phone>55 47 3348-5093</phone>
      <email>giuliano_borges@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Giuliano S Borges, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raquel Pedro Moreira</name>
      <address>
        <city>Araraquara</city>
        <state>São Paulo</state>
        <zip>14802408</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella P Remedi</last_name>
      <phone>55 51 99159-1861</phone>
      <email>gpremedi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raquel P Moreira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daniel Grabarz</name>
      <address>
        <city>Mogi Das Cruzes</city>
        <state>São Paulo</state>
        <zip>08730500</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Grabarz, Dr</last_name>
      <phone>(11) 4795-4795</phone>
      <email>pesquisaclinica@centrooncologico.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Leila Oliveira</last_name>
      <phone>(11) 4795-4795</phone>
      <email>pesquisaclinica@centrooncologico.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Grabarz, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monique Celeste Tavares</name>
      <address>
        <city>São Paulo</city>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique C Tavares, Doctor</last_name>
      <phone>+55 11 2189-5000</phone>
      <phone_ext>5138</phone_ext>
      <email>monique.tavares@accamargo.org.br</email>
    </contact>
    <contact_backup>
      <last_name>Joao Paulo S Lima, Doctor</last_name>
      <phone>+55 11 2189-5000</phone>
      <phone_ext>5138</phone_ext>
      <email>joao.lima@accamargo.org.br</email>
    </contact_backup>
    <investigator>
      <last_name>Monique C Tavares, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joao Paulo S Lima, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast carcinoma</keyword>
  <keyword>receptors 2 (HER2)</keyword>
  <keyword>biosimilar</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>Zedora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

